An open-label cohort study showed brodalumab (Siliq) was an effective and safe treatment option for patients with hidradenitis suppurativa (HS).
The study included 10 participants with moderate to severe HS and no history of inflammatory bowel disease. Brodalumab was administered at 210 mg/1.5 mL subcutaneously at weeks 0, 1, and 2 followed by every 2 weeks until week 24. At weeks 12 and 24, the researchers assessed clinical response, using the Hidradenitis Suppurativa Clinical Response (HiSCR), Sartorius, and International Hidradenitis Suppurativa Severity Score System (IHS4), along with ultrasound and skin biopsies, as well as documented grade 2/3 adverse events associated with brodalumab treatment.
You may also like...
Over 80% of Patients With HS Use Alternative Medicine
Which HS Treatment Option Is Associated With Better Response?
Overall, 100% of participants achieved HiSCR and 80% achieved IHS4 category change at week 12. The researchers found that HiSCR achievement occurred as early as week 2 and noted that this was likely due to the unique blockade by brodalumab of IL-17A, IL-17C, and IL-17F. In addition, they observed significant improvements in pain, itch, quality of life, and depression.
No grade 2/3 adverse events were reported, they added.
“Brodalumab was well tolerated in this HS cohort with no serious adverse events and rapid improvement in clinical outcomes,” the researchers concluded. “Alterations in dose frequency may be required in those with advanced disease which requires further exploration.”
Frew JW, Navrazhina K, Grand D, et al. The Effect of Subcutaneous Brodalumab upon Clinical Disease Activity in Hidradenitis Suppurativa: An Open Label Cohort Study [published online May 13, 2020]. J Am Acad Dermatol. doi:10.1016/j.jaad.2020.05.007